Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    TNT Trial (2005): Intensive lipid lowering with atorvastatin in patients with Stable CAD

    TNT Trial visual abstract

    TNT Trial Summary: LaRosa et al. randomized 10,001 patients with CAD defined by prior MI, prior or current anginal symptoms with evidence of CAD, prior revascularization to either high dose 80 mg atorvastatin or low dose 10 mg atorvastatin. Their objective was to assess if atorvastatin 80 mg PO daily have a greater reduction in CV events when compared to 10 mg atorvastatin in patients with stable CAD and hyperlipidemia. The results showed a significant decrease in major CV events. (P<0.001; NNT 45) These events were composite of CAD mortality, MI, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The authors of the TNT trial concluded that intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit when compared to low-dose daily 10 mg atorvastatin.

    Source: NEJM